opioid epidemic

View All

Opioid-Induced Respiratory Depression Market Outlook
Opioid-Induced Respiratory Depression: Unveiling the Silent Threat

In recent years, the misuse and abuse of opioids have become a growing concern worldwide, with devastating consequences for public health. While the immediate dangers of opioid overdose are well-documented, a silent and potentially lethal complication often lurks in the shadows—opioid-induced respiratory depression...

Find More

narcan-approval-for-opioid-use-disorder-treatment
How Decisive Will The OTC Approval of NARCAN Be In The Fight Against The Opioid Epidemic?

On March 29, 2023, the FDA made the landmark decision to approve Emergent BioSolutions’ NARCAN nasal spray for over-the-counter (OTC) and nonprescription use, making it the first naloxone product to be approved for use without a prescription. With about 80,000 fatal opioid overdoses every year, this could potent...

Find More

Chronic Pain Market Landscape | Chronic Pain Pipeline | Osteoarthritis
Emerging Therapies in the Chronic Pain Pipeline Transforming the Chronic Pain Market Landscape

More than 100 million people are living with one or the other form of Chronic Pain in the USA, says the Institute of Medicine. The available treatments to tackle cancer, as well as non-cancer pain, include nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, opioids, or combinations of opioids and non-narc...

Find More

Tesaro’s Zejula; Mylan on EpiPen; Ohio sues drugmakers; ATUM, Horizon Discovery Announce deal

Tesaro and its new med Zejula are on the block, but bidders aren't rushing in Just ahead of the year’s biggest download of cancer data, the maker of a closely watched drug has put itself up for sale, according to The Wall Street Journal. That’s Tesaro, whose PARP inhibitor Zejula won FDA approval in March. That med ...

Find More